Insulet reports Q2 2026 revenue of $802M, up 23.5%
Omnipod revenue grew 24.6% to $795.9M, net income was $95M, and FY2026 guidance was updated.
See the latest news and media coverage for Insulet. We track all announcements, press releases, and industry mentions in real time, all in one place.
Maker of tubeless insulin delivery systems
insulet.comLast updated
In short: Insulet reported strong Q2 2026 revenue growth but lowered its full-year sales outlook following product recalls and a major legal setback.
Omnipod revenue grew 24.6% to $795.9M, net income was $95M, and FY2026 guidance was updated.
The award highlights leadership in workforce, finance, innovation, and sustainability, reflecting the company's mission-driven culture.
Spain becomes the 20th country for Omnipod 5, compatible with Abbott FreeStyle Libre 2 Plus and Dexcom G7 sensors.
The company will host a conference call at 8 a.m. ET on the same day.
A significant current burden for Insulet is a shareholder lawsuit, which according to GlobeNewswire on 14.09.2026 ...
The Insulet stock (ISIN US45784P1012) stands in September 2026 in the tension field between a clear profit increase in the second ...
In May, Insulet Corporation (PODD) issued a recall affecting millions of its Omnipod insulin delivery devices after some lots ...
Insulet Corporation delivered strong Q2 2026 results with 23.5% revenue growth, strong customer additions, and solid ...
Track Insulet and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Insulet and other trending companies.